DNAprint buys assets of Ellipsis Biotherapeutics

By Ted A. Knutson

Washington, Dec. 23 - DNAprint genomics Inc. said it acquired assets Monday used in the drug and diagnostic discovery business of Toronto-based Ellipsis Biotherapeutics Corp.

Prior to the acquisition, Ellipsis performed contract genotyping for academic centers, hospitals, human health care corporations and biotech companies. Its diverse services include human, plant and animal analyses.

The DNAprint will continue the Ellipsis business through a wholly owned subsidiary named Ellipsis Biotherapeutics Corp.

The acquired assets consist of Ellipsis' operating assets, including genotyping equipment, automated sample preparation devices, DNA preparation, measurement and amplification technologies, laboratory equipment, computers and office supplies related to these activities, the corporate premises, name and logo and certain intellectual property and committed contracts.

In consideration for the Ellipsis assets, DNAprint issued 6.5 million common shares to Ellipsis and assumed Ellipsis liabilities in the approximate amount of $300,000.

Based in Sarasota, Fla., DNAprint is a genomic research company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.